Trajan Group Holdings logo
TRJ

Trajan Group Holdings

Pharmaceuticals, Biotechnology & Life Sciences

Trajan Group Holdings develops and manufactures analytical and life sciences instruments and devices. The company focuses on creating solutions for biological, environmental, and food-related measurements, aiming to improve personal health through scientific tools. Trajan partners in producing critical components and materials for analytical workflow and measurement.

Short position

short percentage0.00%
reported shorts1.4K
shares on issue152.864M

Trajan Group Holdings (ASX:TRJ) has 0.00% of its shares on issue reported as short positions as of 17 July 2026, or about 1,406 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. TRJ is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Price & short interest

Toggle series, zoom, and compare · ASIC daily, T+4

Trajan Group Holdings (TRJ) short interest history

TRJ Short Interest History

30-day change
+0.00pp
90-day change
+0.00pp
1-year change
+0.00pp
All-time high
0.01% (June 2024)
All-time low
0.00% (January 2022)

Is TRJ heavily shorted?

Not especially: 0.00% short interest is modest by ASX standards. ASIC requires positions of 0.01% of issued capital or $100,000 (whichever is less) to be reported.

How has TRJ's short interest changed recently?

Over the past 30 days Trajan Group Holdings's short interest has been broadly stable, and over 90 days it has been broadly stable. The current level is 0.00% of shares on issue.

What is the highest TRJ's short interest has been?

Since 2021, Trajan Group Holdings's short interest peaked at 0.01% in June 2024 and bottomed at 0.00% in January 2022.

Where does this data come from?

All figures are sourced from daily ASIC short position reports, published with a four trading-day (T+4) delay. Shorted aggregates the full history since 2021. See our methodology.